Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

被引：0

作者：

Meletios Dimopoulos

Michael Wang

Vladimir Maisnar

Jiri Minarik

William Bensinger

Maria-Victoria Mateos

Mihaela Obreja

Julie Blaedel

Philippe Moreau

机构：

[1] National and Kapodistrian University of Athens,School of Medicine

[2] The University of Texas MD Anderson Cancer Center,undefined

[3] Faculty Hospital and Medical Faculty of Charles University in Hradec Kralove,undefined

[4] University Hospital Olomouc,undefined

[5] Medical Faculty of Palacky University Olomouc,undefined

[6] Fred Hutchinson Cancer Research Center,undefined

[7] Hospital Clinico Universitario de Salamanca-IBSAL,undefined

[8] Amgen,undefined

[9] Inc.,undefined

[10] University of Nantes,undefined

来源：

Journal of Hematology & Oncology | / 11卷

关键词：

Clinical research; Clinical trials; Multiple myeloma; Myeloma therapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[11] DARATUMUMAB SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA
Katalinic, D.
HAEMATOLOGICA, 2017, 102 : 526 - 527
[12] Interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma
Stewart, A. K.
Rajkumar, S. V.
Dimopoulos, M. A.
Mihaylov, G. G.
Goranova-Marinova, V.
Rajnics, P.
Suvorov, A.
Jakubowiak, A. J.
San-Miguel, J. F.
Zojwalla, N.
Moreau, P.
Palumbo, A.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 20 - 20
[13] Economic evaluation of carfilzomib plus lenalidomide plus dexamethasone (KRd) vs. lenalidomide plus dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
Jakubowiak, Andrzej J.
Benedict, Agnes
Panjabi, Sumeet
Houisse, Ivan
Campioni, Marco
Giannopoulou, Andromachi
Aggarwal, Sanjay
Fonseca, Rafael
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[14] Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Siegel, David S.
Dimopoulos, Meletios A.
Ludwig, Heinz
Facon, Thierry
Goldschmidt, Hartmut
Jakubowiak, Andrzej
San-Miguel, Jesus
Obreja, Mihaela
Blaedel, Julie
Stewart, A. Keith
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 728 - +
[15] CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND EARLY PROGRESSION DURING PRIOR THERAPY: SECONDARY ANALYSIS FROM THE PHASE 3 STUDY ASPIRE (NCT01080391)
Rocafiguera Albert, Oriol
Laura, Rosinol
Jesus F, San-Miguel
Heinz, Ludwig
Meletios A, Dimopoulos
Tamas, Masszi
Spic
Ivan, Ka
Roman, Hajek
David S, Siegel
Georgi G, Mihaylov
Vesselina, Goranova-Marinova
Peter, Rajnics
Aleksandr, Suvorov
Ruben, Niesvizky
Andrzej J, Jakubowiak
Mihaela, Obreja
Sanjay, Aggarwal
Philippe, Moreau
Antonio, Palumbo
HAEMATOLOGICA, 2016, 101 : 27 - 28
[16] Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
Dimopoulos, Meletios A.
Stewart, A. Keith
Masszi, Tamas
Spicka, Ivan
Oriol, Albert
Hajek, Roman
Rosinol, Laura
Siegel, David
Mihaylov, Georgi G.
Goranova-Marinova, Vesselina
Rajnics, Peter
Suvorov, Aleksandr
Niesvizky, Ruben
Jakubowiak, Andrzej
San-Miguel, Jesus
Ludwig, Heinz
Palumbo, Antonio
Obreja, Mihaela
Aggarwal, Sanjay
Moreau, Philippe
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (03) : 404 - 413
[17] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
Vesole, David H.
Bilotti, Elizabeth
Richter, Joshua R.
McNeill, Ann
McBride, Laura
Raucci, Laura
Anand, Palka
Bednarz, Urszula
Ivanovski, Kristin
Smith, Judith
Batra, Veena
Aleman, Adolfo
Sims, Taliah
Guerrero, Laura
Mato, Anthony
Siegel, David S.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 52 - 59
[18] CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN MULTIPLE MYELOMA IN RELAPSE ACCORDING TO TREATMENT LINE: INTERMEDIATE SECONDARY ANALYSIS OF ASPIRE (PHASE 3, NCT01080391)
Oriol, A.
Rosinol, L.
San-Miguel, J.
Meletios, Dimopoulos A.
Stewart, A. K.
Rajkumar, S., V
Masszi, T.
Hajek, R.
Siegel, D.
Georgi, Mihaylov G.
Goranova-Marinova, V
Rajnics, P.
Suvorov, A.
Niesvizky, R.
Jakubowiak, A.
Ludwig, H.
Zojwalla, N.
Moreau, P.
Palumbo, A.
HAEMATOLOGICA, 2015, 100 : 46 - 46
[19] Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)
Jasielec, Jagoda
Dytfeld, Dominik
Griffith, Kent A.
McDonnell, Kathryn
Lebovic, Daniel
Kandarpa, Malathi
Anderson, Tara
Mietzel, Melissa
Faham, Malek
Lee, Liana
Levy, Joan
Alonge, Mattina
Rosebeck, Shaun
Kaminski, Mark
Jakubowiak, Andrzej
BLOOD, 2014, 124 (21)
[20] Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma
Garcia-Guinon, Antoni
Charry, Paola Andrea
Jimenez, Maria
Sarra, Josep
Delgado, Izarbe
de la Torre, Laura Segura
Santaliestra, Marta
Garcia-Pintos, Marta
Gonzalez, Yolanda
Senin, Alicia
Motllo, Cristina
Abella, Eugenia
Cabezudo, Elena
Granell, Miquel
Sancho, Esther
Herranz, Maria Jose
Seres, Yasmina
Gironella, Mercedes
Soler, Juan Alfons
Marti-Tutusaus, Josep Maria
Ben Azaiz, Ran
de Larrea, Carlos Fernandez
ANNALS OF HEMATOLOGY, 2025, 104 (02) : 1177 - 1186

← 1 2 3 4 5 →